Not So Fast: FDA Announces End Of QUIK 510(k) Pilot
Executive Summary
The pilot program from the US agency is set to close on 30 May after regulators found the competing eSTAR project offered more advantages.
You may also be interested in...
Lucky STAR: FDA’s eSTAR Pilot Aims To Make 510(k) Process Smoother
Nine device makers will soon have the chance to enroll in a voluntary eSTAR pilot program that the US agency says will make the premarket review process more efficient and consistent. The design and structure of an electronic Submission Template And Resource – or eSTAR – template is similar to templates used by FDA reviewers. An eSTAR won’t change the agency’s statutory or data requirements for sponsors to show substantial equivalence to predicate devices.
Proposed 510(k) Changes Elicit Some Industry Skepticism
Two 510(k) pilots from US FDA indicate the agency's desire for faster, easier clearances. But some observers aren’t sure if they’ll lead to real improvements.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.